Tyrosine Kinase Inhibitors as Cancer Therapy

References

• Parker R.C., Varmus H.E., Bishop J.M. Cellular homologue (c-src) of the transforming gene of Rous sarcoma virus: isolation, mapping, and transcriptional analysis of c-src and flanking regions. Proc. Natl Acad. Sci. USA 1981; 78: 5842–5846
   PubMed Web of Science ®Google Scholar
• Davis R.L., Konopka J.B., Witte O.N. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol. Cell Biol. 1985; 5: 204–213
   PubMed Web of Science ®Google Scholar
• Weiss A., Schlessinger J. Switching signals on or off by receptor dimerization. Cell 1998; 94: 277–280
   PubMed Web of Science ®Google Scholar
• Pawson T. SH2 and SH3 domains in signal transduction. Adv. Cancer Res. 1994; 64: 87–110
   PubMed Web of Science ®Google Scholar
• Schlessinger J. SH2/SH3 signaling proteins. Curr. Opin. Genet. Dev. 1994; 4: 25–30
   PubMedGoogle Scholar
• van der Geer P., Pawson T. The PTB domain: a new protein module implicated in signal transduction. Trends Biochem. Sci. 1995; 20: 277–280
   PubMed Web of Science ®Google Scholar
• Hunter T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1998; 353: 583–605
   PubMed Web of Science ®Google Scholar
• Rodrigues G.A., Park M. Oncogenic activation of tyrosine kinases. Curr. Opin. Genet. Dev. 1994; 4: 15–24
   PubMedGoogle Scholar
• Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc. Natl Acad. Sci. USA 1985; 82: 1810–1814
   PubMed Web of Science ®Google Scholar
• Chan L.C., Karhi K.K., Rayter S.I., Heisterkamp N., Eridani S., Powles R., Lawler S.D., Groffen J., Foulkes J.G., Greaves M.F., Wiedemann L.M. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987; 325: 635–637
   PubMed Web of Science ®Google Scholar
• Clark S.S., McLaughlin J., Crist W.M., Champlin R., Witte O.N. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 1987; 235: 85–88
   PubMed Web of Science ®Google Scholar
• Pendergast A.M., Gishizky M.L., Havlik M.H., Witte O.N. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol. Cell. Biol. 1993; 13: 1728–1736
   PubMed Web of Science ®Google Scholar
• Wetzler M., Talpaz M., Van Etten R.A., Hirsh-Ginsberg C., Beran M., Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J. Clin. Investig. 1993; 92: 1925–1939
   PubMed Web of Science ®Google Scholar
• McWhirter J.R., Galasso D.L., Wang J.Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell Biol. 1993; 13: 7587–7595
   PubMed Web of Science ®Google Scholar
• Nichols G.L., Raines M.A., Vera J.C., Lacomis L., Tempst P., Golde D.W. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994; 84: 2912–2918
   PubMed Web of Science ®Google Scholar
• Oda T., Heaney C., Hagopian J.R., Okuda K., Griffin J.D., Druker B.J. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 1994; 269: 22925–22928
   PubMed Web of Science ®Google Scholar
• ten Hoeve J., Arlinghaus R.B., Guo J.Q., Heisterkamp N., Groffen J. Tyrosine phosphorylation of CRKL in philadelphia+leukemia. Blood 1994; 84: 1731–1736
   PubMed Web of Science ®Google Scholar
• Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• Elefanty A.G., Hariharan I.K., Cory S. bcr-abl, the hallmark of chronic myeloid leukemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990; 9: 1069
   PubMed Web of Science ®Google Scholar
• Kelliher M.A., McLaughlin J., Witte O.N., Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr-abl. PNAS 1990; 87: 6649–6653
   PubMed Web of Science ®Google Scholar
• Janssen J.W., Ridge S.A., Papadopoulos P., et al. The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event. Br. J. Haematol. 1995; 90: 222–224
   PubMed Web of Science ®Google Scholar
• Peeters P., Raynaud S.D., Cools J., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90: 2535–2540
   PubMed Web of Science ®Google Scholar
• Lacronique V., Boureux A., Valle V.D., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309–1312
   PubMed Web of Science ®Google Scholar
• Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307–316
   PubMed Web of Science ®Google Scholar
• Morris S.W., Kirstein M.N., Valentine M.B., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281–1284
   PubMed Web of Science ®Google Scholar
• Shiota M., Nakamura S., Ichinohasama R., et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954–1960
   PubMed Web of Science ®Google Scholar
• Macdonald D., Aguiar R.C., Mason P.J., Goldman J.M., Cross N.C. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia 1995; 9: 1628–1630
   PubMed Web of Science ®Google Scholar
• Aguiar R.C., Macdonald D., Mason P.J., Cross N.C., Goldman J.M. Myeloproliferative disorder associated with 8p11 translocations. Blood 1995; 86: 834–835
   PubMed Web of Science ®Google Scholar
• Chesi M., Nardini E., Brents L.A., et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 1997; 16: 260–264
   PubMed Web of Science ®Google Scholar
• Bongarzone I., Pierotti M.A., Monzini N., et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989; 4: 1457–1462
   PubMed Web of Science ®Google Scholar
• Grieco M., Santoro M., Berlingieri M.T., et al. PTC is novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990; 60: 557–563
   PubMed Web of Science ®Google Scholar
• Klugbauer S., Demidchik E.P., Lengfelder E., Rabes H.M. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res. 1998; 58: 198–203
   PubMed Web of Science ®Google Scholar
• Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C., Della Porta G. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 1992; 7: 237–242
   PubMed Web of Science ®Google Scholar
• Beimfohr C., Klugbauer S., Demidchik E.P., Lengfelder E., Rabes H.M. NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident. Int. J. Cancer 1999; 80: 842–847
   PubMed Web of Science ®Google Scholar
• Soman N.R., Correa P., Ruiz B.A., Wogan G.N. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc. Natl Acad. Sci. USA 1991; 88: 4892–4896
   PubMed Web of Science ®Google Scholar
• Knezevich S.R., McFadden D.E., Tao W., Lim J.F., Sorensen P.H. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat. Genet. 1998; 18: 184–187
   PubMed Web of Science ®Google Scholar
• Liu Q., Schwaller J., Kutok J., et al. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. Embo. J. 2000; 19: 1827–1838
   PubMed Web of Science ®Google Scholar
• Ponder B.A. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. Cancer Surv. 1995; 25: 195–205
   PubMedGoogle Scholar
• Kahn M.A., Cote G.J., Gagel R.F. RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 1996; 82: 288–294
   PubMed Web of Science ®Google Scholar
• Donis-Keller H., Dou S., Chi D., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 1993; 2: 851–856
   PubMed Web of Science ®Google Scholar
• Mulligan L.M., Eng C., Healey C.S., et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet. 1994; 6: 70–74
   PubMed Web of Science ®Google Scholar
• Takahashi M. Oncogenic activation of the ret protooncogene in thyroid cancer. Crit. Rev. Oncog. 1995; 6: 35–46
   PubMed Web of Science ®Google Scholar
• Marsh D.J., Learoyd D.L., Andrew S.D., et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin. Endocrinol. (Oxf) 1996; 44: 249–257
   PubMed Web of Science ®Google Scholar
• Wong A.J., Ruppert J.M., Bigner S.H., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl Acad. Sci. USA 1992; 89: 2965–2969
   PubMed Web of Science ®Google Scholar
• Frederick L., Wang X.Y., Eley G., James C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000; 60: 1383–1387
   PubMed Web of Science ®Google Scholar
• Nagane M., Lin H., Cavenee W.K., Huang H.J. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett. 2001; 162(suppl)S17–S21
   PubMedGoogle Scholar
• Kiyoi H., Towatari M., Yokota S., Hamaguchi M., Ohno R., Saito H., Naoe T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333–1337
   PubMed Web of Science ®Google Scholar
• Rombouts W.J., Blokland I., Lowenberg B., Ploemacher R.E. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications. Leukemia 2000; 14: 675–683
   PubMed Web of Science ®Google Scholar
• Nakahara M., Isozaki K., Hirota S., et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998; 115: 1090–1095
   PubMed Web of Science ®Google Scholar
• Taniguchi M., Nishida T., Hirota S., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999; 59: 4297–4300
   PubMed Web of Science ®Google Scholar
• Boissan M., Feger F., Guillosson J.J., Arock M. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J. Leukoc. Biol. 2000; 67: 135–148
   PubMed Web of Science ®Google Scholar
• Kimura A., Nakata Y., Katoh O., Hyodo H. c-Kit point mutation in patients with myeloproliferative disorders. Leuk. Lymphoma 1997; 25: 281–287
   PubMed Web of Science ®Google Scholar
• Klapper L.N., Glathe S., Vaisman N., et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl Acad. Sci. USA 1999; 96: 4995–5000
   PubMed Web of Science ®Google Scholar
• King C.R., Kraus M.H., Aaronson S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229: 974–976
   PubMed Web of Science ®Google Scholar
• Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• Yamauchi H., Stearns V., Hayes D.F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J. Clin. Oncol. 2001; 19: 2334–2356
   PubMed Web of Science ®Google Scholar
• Hayes D.F., Thor A.D. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin. Oncol. 2002; 29: 231–245
   PubMed Web of Science ®Google Scholar
• Sedlacek H.H. Kinase inhibitors in cancer therapy: a look ahead. Drugs 2000; 59: 435–476
   PubMed Web of Science ®Google Scholar
• Kolibaba K.S., Druker B.J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta 1997; 1333: F217–F248
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995; 1: 27–31
   PubMed Web of Science ®Google Scholar
• Cherrington J.M., Strawn L.M., Shawver L.K. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv. Cancer Res. 2000; 79: 1–38
   PubMed Web of Science ®Google Scholar
• Poon R.T., Fan S.T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 2001; 19: 1207–1225
   PubMed Web of Science ®Google Scholar
• Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843–845
   PubMed Web of Science ®Google Scholar
• Kondo S., Asano M., Matsuo K., Ohmori I., Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta 1994; 1221: 211–214
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res. 2000; 55: 15–35
   PubMedGoogle Scholar
• Abdulrauf S.I., Edvardsen K., Ho K.L., Yang X.Y., Rock J.P., Rosenblum M.L. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J. Neurosurg. 1998; 88: 513–520
   PubMed Web of Science ®Google Scholar
• Johnson J.P., Bruce J.N. Angiogenesis in human gliomas: prognostic and therapeutic implications. EXS 1997; 79: 29–46
   PubMedGoogle Scholar
• Shim J.W., Koh Y.C., Ahn H.K., Park Y.E., Hwang D.Y., Chi J.G. Expression of bFGF and VEGF in brain astrocytoma. J. Korean Med. Sci. 1996; 11: 149–157
   PubMedGoogle Scholar
• Dirix L.Y., Vermeulen P.B., Hubens G., et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann. Oncol. 1996; 7: 843–848
   PubMed Web of Science ®Google Scholar
• Ishigami S.I., Arii S., Furutani M., et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer 1998; 78: 1379–1384
   PubMed Web of Science ®Google Scholar
• Takahashi Y., Tucker S.L., Kitadai Y., et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. 1997; 132: 541–546
   PubMed Web of Science ®Google Scholar
• Takanami I., Tanaka F., Hashizume T., Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 1997; 17: 2811–2814
   PubMed Web of Science ®Google Scholar
• Volm M., Koomagi R., Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer 1997; 74: 64–68
   PubMed Web of Science ®Google Scholar
• Fontanini G., Vignati S., Lucchi M., et al. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br. J. Cancer 1997; 75: 1295–1301
   PubMed Web of Science ®Google Scholar
• Toi M., Hoshina S., Takayanagi T., Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res. 1994; 85: 1045–1049
   PubMedGoogle Scholar
• Al-Obeidi F.A., Lam K.S. Development of inhibitors for protein tyrosine kinases. Oncogene 2000; 19: 5690–5701
   PubMed Web of Science ®Google Scholar
• Al-Obeidi F.A., Wu J.J., Lam K.S. Protein tyrosine kinases: structure, substrate specificity, and drug discovery. Biopolymers 1998; 47: 197–223
   PubMed Web of Science ®Google Scholar
• Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996; 14: 737–744
   PubMed Web of Science ®Google Scholar
• Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999; 17: 2639–2648
   PubMed Web of Science ®Google Scholar
• Baselga J. Clinical trials of Herceptin® (trastuzumab). Eur. J. Cancer 2001; 37(Suppl 1)18–24
   PubMedGoogle Scholar
• Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 2001; 8: 3–9
   PubMed Web of Science ®Google Scholar
• Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors and anticancer agents. Drugs 2000; 60: 25–32, discussion 41–2
   PubMed Web of Science ®Google Scholar
• Shin D.M., Donato N.J., Perez-Soler R., et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 2001; 7: 1204–1213
   PubMed Web of Science ®Google Scholar
• Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001; 19: 3234–3243
   PubMed Web of Science ®Google Scholar
• Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94: 1593–1611
   PubMed Web of Science ®Google Scholar
• Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 2001; 19: 843–850
   PubMed Web of Science ®Google Scholar
• Margolin K., Gordon M.S., Holmgren E., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 2001; 19: 851–856
   PubMed Web of Science ®Google Scholar
• Chen H.X., Gore-Langton R.E., Cheson B.D. Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology 2001; 15: 1017–1026
   PubMed Web of Science ®Google Scholar
• Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001; 344: 1031–1037
   PubMed Web of Science ®Google Scholar
• Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 2000; 295: 139–145
   PubMed Web of Science ®Google Scholar
• Okuda K., Weisberg E., Gilliland D.G., Griffin J.D. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001; 97: 2440–2448
   PubMed Web of Science ®Google Scholar
• Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925–932
   PubMed Web of Science ®Google Scholar
• Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001; 344: 1052–1056
   PubMed Web of Science ®Google Scholar
• Blanke C.D., von Mehren M., Joensuu H., Roberts P.J., Eisenberg B., Heinrich M., Druker B., Tuveson D., Dimitrijevic S., Silberman S.L., Demetri G.D. Evaluation of the safety and efficacy of an oral molecularly targeted therapy, STI571 in patients with unresectable or metastatic gastrointestinal stromal tumors expressing c-KIT (CD117). Proc. Am. Sco. Clin. Oncol. 2001; 20(pt 1)1a
   Google Scholar
• Van Oosterum A.T., Judson I., Verweij J., Di Paola E., van Glabbeke M., Dimitrijevic S., Nielsen O. STI571, an active drug in metastatic gastro intestinal stromal tumors an EORTC Phase I study. Proc. Am. Soc. Clin. Oncol. 2001; 20(pt. 1)1a
   Google Scholar
• Ko Y.J., Small E.J., Kabbinavar F., et al. A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2001; 7: 800–805
   PubMed Web of Science ®Google Scholar
• Eckhardt S.G., Rizzo J., Sweeney K.R., et al. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J. Clin. Oncol. 1999; 17: 1095–1104
   PubMed Web of Science ®Google Scholar
• Baselga J., Averbuch S.D. ZD1839 (‘Iressa’) as an anticancer agent. Drugs 2000; 60: 33–40, discussion 41–2
   PubMed Web of Science ®Google Scholar
• Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 2001; 19: 3267–3279
   PubMed Web of Science ®Google Scholar
• Mesters R.M., Padro T., Bieker R., et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98: 241–243
   PubMed Web of Science ®Google Scholar
• Kuenen B.C., Rosen L., Smit E.F., Parson M.R., Levi M., Ruijter R., Huisman H., Kedde M.A., Noordhuis P., van der Vijgh W.J., Peters G.J., Cropp G.F., Scigalla P., Hoekman K., Pinedo H.M., Giaccone G. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 2002; 20: 1657–1667
   PubMed Web of Science ®Google Scholar
• Mellinghoff I.K., Sawyers C. Kinase Inhibitor Therapy in Cancer. PPO Updates. Lippincott, Williams and Wilkins, New York
   Google Scholar
• Mahon F.X., Deininger M.W., Schultheis B., et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: diverse mechanisms of resistance. Blood 2000; 96: 1070–1079
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C., Barni R., le Coutre P., et al. Role of alpha 1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor ST1571. J. Natl Cancer Inst. 2000; 92: 1641–1650
   PubMed Web of Science ®Google Scholar
• Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880
   PubMed Web of Science ®Google Scholar
• Kano Y., Akutsu M., Tsunoda S., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97: 1999–2007
   PubMed Web of Science ®Google Scholar
• Topaly J., Zeller W.J., Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001; 15: 342–347
   PubMed Web of Science ®Google Scholar
• Moulder S.L., Yakes M., Muthuswamy S.K., Bianco R., Simpson J.F., Arteaga C. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001; 24: 887–895
   Google Scholar